Consolidated Statements of Operations - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jun. 30, 2019 |
Jun. 30, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
Dec. 31, 2018 |
Dec. 31, 2017 |
|
| Total revenue | $ 420,337 | $ 39,780 | $ 663,075 | $ 108,332 | $ 308,129 | $ 898,084 |
| Cost of Revenue | 281,952 | 9,761 | 404,080 | 27,685 | 137,897 | 726,252 |
| Gross profit | 138,385 | 30,019 | 258,995 | 80,647 | 170,232 | 171,832 |
| Operating Expenses: | ||||||
| Selling expenses | 80,457 | 0 | 89,666 | 0 | ||
| Compensation - officers | 30,000 | 30,000 | 61,675 | 60,000 | 120,000 | 120,000 |
| Research and development | 64,716 | 56,771 | 126,720 | 107,789 | 221,510 | 208,238 |
| Professional fees | 216,865 | 513,736 | 572,139 | 563,897 | 960,846 | 107,899 |
| General and administrative | 238,714 | 135,889 | 349,170 | 205,052 | 451,597 | 256,225 |
| Total Operating Expenses | 630,752 | 736,396 | 1,199,370 | 936,738 | 1,753,953 | 692,362 |
| Loss from Operations | (492,367) | (706,377) | (940,375) | (856,091) | (1,583,721) | (520,530) |
| Other Income (Expense): | ||||||
| Interest income (expense), net | 343 | (388,901) | 1,068 | (443,020) | (440,943) | (105,831) |
| Other income | 1,980 | 0 | 1,980 | 0 | ||
| Total other expense | 2,323 | (388,901) | 3,048 | (443,020) | (440,943) | (105,831) |
| Loss before income taxes | (490,044) | (1,905,278) | (937,327) | (1,299,111) | (2,024,664) | (626,361) |
| Tax expense | 0 | 0 | 0 | 0 | ||
| Net Loss | $ (490,044) | $ (1,095,278) | $ (937,327) | $ (1,299,111) | $ (2,024,664) | $ (626,361) |
| Weighted Average Number of Common Shares Outstanding - Basic and Diluted | 40,959,741 | 34,641,405 | 40,938,725 | 34,417,219 | 37,778,614 | 34,571,706 |
| Net Loss Per Common Share: | ||||||
| Basic and Diluted | $ (0.01) | $ (0.03) | $ (0.02) | $ (0.04) | $ (0.05) | $ (0.02) |
| Revenue [Member] | ||||||
| Total revenue | $ 420,337 | $ 36,580 | $ 660,075 | $ 97,757 | $ 285,929 | $ 891,513 |
| Revenue Related Party [Member] | ||||||
| Total revenue | $ 0 | $ 3,200 | $ 3,000 | $ 10,575 | $ 22,200 | $ 6,571 |
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net amount of operating interest income (expense). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue and income classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Expenses recognized in the period that are directly related to the selling and distribution of products or services. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS). No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|